Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality
暂无分享,去创建一个
H. Dombret | M. Robin | P. Fenaux | M. Sébert | L. Adès | R. Itzykson | G. Socié | E. Raffoux | E. Lengliné | D. Michonneau | R. Peffault de Latour | A. Xhaard | A. S. Del Galy | A. Marouf | F. Sicre de Fontebrune | C. Frieri
[1] M. Sorror,et al. Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts , 2020, Annals of Internal Medicine.
[2] C. Bloomfield,et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study , 2019, Leukemia.
[3] L. Möllgård,et al. Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. , 2019, Blood.
[4] A. Letai,et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.
[5] Robert K. Stuart,et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] W. Wood,et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. , 2017, Blood.
[7] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[8] H. Deeg,et al. Therapy for Hematologic Cancers in Older Patients, Quality of Life, and Health Economics: Difficult Decisions. , 2015, JAMA oncology.
[9] E. Estey,et al. Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Cazzola,et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. , 2013, Blood.
[11] M. Cazzola,et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] P. Hari,et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. , 2011, JAMA.
[13] H Putter,et al. Tutorial in biostatistics: competing risks and multi‐state models , 2007, Statistics in medicine.
[14] E. Estey,et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). , 2007, Blood.
[15] E. Estey,et al. Prospective Feasibility Analysis of Reduced Intensity Conditioning Regimens (RIC) for Hematopoietic Stem Cell Transplantation (HSCT) in Elderly Patients with AML and MDS. , 2005 .
[16] R Simon,et al. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.